You Can Make Me Dance, Sing or Anything (Even Take the Dog for a Walk, Mend a Fuse, Fold Away the Ironing Board, or Any Other Domestic Shortcomings)

ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors

Retrieved on: 
Wednesday, August 23, 2023
Executive, University, Value chain, ANI, Audit, Health, Capsule, Cardinal Health, MBA, You Can Make Me Dance, Sing or Anything (Even Take the Dog for a Walk, Mend a Fuse, Fold Away the Ironing Board, or Any Other Domestic Shortcomings), MD, Patient, Heel, PBM, CVS Health, Committee on Finance, Management, Nursing, Science, Pharmacy, Covetrus

BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately.

Key Points: 
  • -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy --
    BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the addition of Matthew J. Leonard, R.Ph.
  • Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry.
  • “We are delighted to add Matthew (Matt) Leonard to our Board of Directors.
  • “On the heels of a record quarter and with ANI’s compelling growth trajectory, it’s an exciting time to join the Board.

FTC Acts to Prevent Interlocking Directorate Arrangement, Anticompetitive Information Exchange in EQT, Quantum Energy Deal

Retrieved on: 
Tuesday, August 22, 2023
You Can Make Me Dance, Sing or Anything (Even Take the Dog for a Walk, Mend a Fuse, Fold Away the Ironing Board, or Any Other Domestic Shortcomings), Regulations.gov, Quantum Energy Partners, Tug Hill, Industry, Board, Register, Commission, Federal Trade Commission Act of 1914, Federal, Blog, Social media, Federal Trade Commission, Sale, Competition, Clayton Antitrust Act of 1914, EQT, Acquisition, Federal Register, TMC, THQ, FTC, United Western Minerals Company, Natural gas, Compliance, Quantum, LLC, News, Security (finance), Lithium, Cryptocurrency, Pharmaceutical industry, Microscope
Key Points: 

FTC Acts to Prevent Interlocking Directorate Arrangement, Anticompetitive Information Exchange in EQT, Quantum Energy Deal

Retrieved on: 
Tuesday, August 22, 2023
You Can Make Me Dance, Sing or Anything (Even Take the Dog for a Walk, Mend a Fuse, Fold Away the Ironing Board, or Any Other Domestic Shortcomings), Regulations.gov, Quantum Energy Partners, Tug Hill, Industry, Board, Register, Commission, Federal Trade Commission Act of 1914, Federal, Blog, Social media, Federal Trade Commission, Sale, Competition, Clayton Antitrust Act of 1914, EQT, Acquisition, Federal Register, TMC, THQ, FTC, United Western Minerals Company, Natural gas, Compliance, Quantum, LLC, News, Security (finance), Lithium, Cryptocurrency, Pharmaceutical industry, Microscope

The FTC’s consent order delivers ground-breaking structural relief that prohibits Quantum from occupying an EQT board seat, requires Quantum to divest its EQT shares, prevents anticompetitive information exchange, unwinds a separate anticompetitive joint venture between the two entities, and imposes additional restraints to protect competition.

Key Points: 
  • The FTC’s consent order delivers ground-breaking structural relief that prohibits Quantum from occupying an EQT board seat, requires Quantum to divest its EQT shares, prevents anticompetitive information exchange, unwinds a separate anticompetitive joint venture between the two entities, and imposes additional restraints to protect competition.
  • As the FTC’s complaint states, this arrangement creates an illegal interlocking directorate, which violates Section 8 of the Clayton Act.
  • According to the FTC’s complaint, this joint venture relationship raises additional concerns regarding anticompetitive information exchange and harms competition in the acquisition of mineral rights.
  • The FTC’s proposed consent order resolves the Commission’s concerns while also clearly signaling the antitrust risks of excessive entanglements and anticompetitive information exchange.
  • Further details about the order can be found in the analysis to aid public comment.
  • The Commission vote to issue the complaint and accept the consent agreement for public comment was 3-0.
  • When the Commission issues a consent order on a final basis, it carries the force of law with respect to future actions.

ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors

Retrieved on: 
Tuesday, March 22, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Company, Private Securities Litigation Reform Act, Therapy, Fleming Companies, Inc, University, Conditional sentence, Elan, Growth, Board, You Can Make Me Dance, Sing or Anything (Even Take the Dog for a Walk, Mend a Fuse, Fold Away the Ironing Board, or Any Other Domestic Shortcomings), U.S. Securities and Exchange Commission, AbbVie, Halozyme, Philadelphia College of Osteopathic Medicine, Board of directors, National Society of Certified Healthcare Business Consultants, Government, Science, LLC, Acquisition, Temple University, Pharming, Nasdaq, MBA, CCA Global Partners, COVID-19, Physician, News, Bristol Myers Squibb, ANI, Hormone, Patient, Merck, Management, Pharmaceutical industry, Risk management, Pharmacy, Policy, Director

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced the addition of Renee P. Tannenbaum, Pharm.D., MBA, to its Board of Directors.

Key Points: 
  • ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced the addition of Renee P. Tannenbaum, Pharm.D., MBA, to its Board of Directors.
  • This appointment is effective immediately and increases ANIs Board of Directors to nine members.
  • We are honored to bring Dr. Tannenbaums vast biopharmaceutical commercial experience and expertise to our Board of Directors.
  • I am thrilled to join the Board of Directors at this pivotal point in ANIs trajectory.